Non-Small Cell Lung Cancer

patient care perspectives

by Jeffrey Crawford, MD

Given the large number of targeted therapies that are now available for non–small cell lung cancer (NSCLC), it is essential for patients to receive......READ MORE

patient care perspectives

by Gregory J. Riely, MD, PhD

Although targeted therapy has revolutionized the treatment of non–small cell lung cancer (NSCLC) in those who have specific oncogenetic alterations......READ MORE

patient care perspectives

by Bruce E. Johnson, MD

There are now 8 actionable biomarkers/mutations for which there are agents approved by the US Food and Drug Administration (FDA) to treat patients ......READ MORE

patient care perspectives

by Jeffrey Crawford, MD

Patients with non–small cell lung cancer (NSCLC) require an understanding of the differences between immunotherapy and conventional chemotherapy. T......READ MORE

patient care perspectives

by Bruce E. Johnson, MD

Early broad testing for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) is recommended because of the challenges associated w......READ MORE